UNSPSC 51314318: Bromphenhiramine/dextromethorphan/pseudoephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE503. This VA Drug Class (RE503) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/EXPECTORANT.

UNSPSC 51314318 Bromphenhiramine/dextromethorphan/pseudoephedrine, a Commodity code, does not align with the recent state and local opportunities tagged under it. The three posted solicitations—Seminole County's procurement for naloxone and drug deactivation systems, Texas HHS's Request for Information on direct-to-manufacturer pharmacy programs, and Minnesota's cooperative purchasing RFP for generic multi-source pharmaceuticals and OTC products—focus on naloxone, pharmacy benefit program administration, and broad-category generics and OTC items respectively, not the specific combination cold/allergy medication named in the code. The opportunities reflect actual purchasing for public health emergency response, state pharmaceutical benefit management, and multi-state cooperative bulk acquisition, which fall outside the narrow scope of this branded or generic cold remedy formulation. State and local governments do procure pharmaceuticals and OTC products through cooperative purchasing vehicles and direct health department contracts, but current activity does not evidence demand for this specific medication combination at scale.

The recent opportunities span Florida (Seminole County health procurement), Texas (state HHS RFI), and Minnesota (multistate cooperative), with the Minnesota MMCAP vehicle serving state and local facilities across participating jurisdictions including Oregon. Issuing bodies include county health departments, state health and human services commissions, and state procurement offices administering cooperative purchasing. Seminole County posted an IFB (Solicitation IFB60459723LAS) with a response deadline of July 26, 2023, for naloxone and deactivation systems with quarterly deliveries; Texas HHS issued an RFI (HHS0017013) on April 3, 2026, to explore direct-to-manufacturer pharmacy contracting; and Minnesota's MMCAP released an RFP (S1070000015802) due March 26, 2026, establishing multi-award contracts for generic pharmaceuticals and OTC products through authorized wholesalers. The code shows minimal direct relevance to current state and local procurement activity.